Good morning, ladies and gentlemen, and welcome to Veradermic's conference call to discuss results from the female trial arms of Study 207, a Phase II open-label trial evaluating VDPHL01 for mild to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results